The Inaugural Cancer Precision Medicine Forum 2019 will take place on the 2nd and 3rd of December 2019 in Berlin, Germany. The forum brings together experts from across the globe to share the latest advances in precision oncology. With an intimate set-up of 300 participants, the forum provides an opportunity for engaging debates and collaboration with peers through a variety of interactive formats.
Lars Bullinger, Professor of Personalized Medicine at Charité and Leader of HARMONY Workpackage 2: Definitions of Outcomes, will present and participate in session three of the meeting, titled 'Advancing precision medicine through partnerships, collaboration & funding initiatives'. This session will take place on Day 1 of the Forum.
Commenting on the ongoing research project being conducted by HARMONY, Professor Bullinger remarks,'Our pilot study will improve how we capture data on the heterogeneity of hematologic malignancies such as acute myeloid leukemia, which we hope will translate into individualized care for patients and prove the valuable role of HARMONY in using Big Data for Better Outcomes.'
There is a pressing need for increased collaboration among stakeholders to advance precision medicine in oncology. Transparent and systematic data sharing is an effective tool that will help to achieve this goal and the session at this year's Forum Meeting will explore the approaches being undertaken by initiatives across Europe.
Click here to visit the official website of the Cancer Prescision Medicine Forum 2019.
Download the latest edition of the agenda here
HARMONY research projects are addressing critical unanswered research questions in Hematologic Malignancies (HM) to increase our understanding of each disease and improve outcomes for patients.
Read more about HARMONY > | Read more about our current projects >
If you are interested in becoming involved with the HARMONY Alliance, please contact us >
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
